The Tayside Medicines Monitoring Unit (MEMO)

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 323-336

  Wei, Li ^a,b   Parkinson, John ^a   MacDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Ambulance and emergency department data; Case control design and MEMO studies; Diabetes Audit and Research in Tayside Scotland (DARTS) database; Genetic data phenotypic linkage; Health Informatics Centre (HIC); MEMO HIC NHS Clinical Interface Unit; NHS Clinical Technology Centre; Optical character recognition (OCR) software; Randomized simplified trials and randomized epidemiology; Tayside Medicines Monitoring Unit (MEMO)

Indexed keywords

EID: 84889436895     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch21     Document Type: Chapter

References (78)

1. MacDonald TM, McDevitt DG. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, ed., Pharmacoepidemiology, 2nd edn. Chichester: John Wiley & Sons, 1994; pp. 245-55.
2. Beardon PHG, Brown SV, McDevitt DG. Four-year mortality among cimetodine takers in Tayside: results of a controlled study using record linkage. Pharm Med 1988; 3: 333-9.
3. NHS in Scotland, Information and Statistics Division. SMR Data Manual, version 1.3. Edinburgh: NHSiS, 2000. Available at: http://www.isdscotland.org/isd/files/SMRDM_intro.pdf.
4. International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Available at: http://www.pharmacoepi.org/resources/guidelines_08027.cfm.
5. Wilson P. Commentary: legal issues of data anonymisation in research. BMJ 2004; 328: 1300-1.
6. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 9th revision, vol. 1. Geneva: World Health Organization, 1977.
7. Office of Population Censuses and Surveys. Tabular List of the Classification of Surgical Operations and Procedures, 4th revision. London: HMSO, 1990.
8. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 1992.
9. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ. 1997; 315: 524-8.
10. Carstairs V. Deprivation and health in Scotland. Health Bull (Edinb) 1990; 48: 162-75.
11. Wei L, MacDonald TM, Davey PG. Relation between socioeconomic deprivation and statin prescribing in post myocardial infarction patients: a population based study. Pharmacoepidemiol Drug Saf 2002; 11 (suppl): S151.
12. Libby G, Smith A, McEwan NF, Chien PFW, Greene SA, Forsyth JS et al. The Walker Project: a longitudinal study of 48,000 children born 1952-66 (aged 36-50 years in 2002) and their families. Study methodology. Paediatr Perinat Epidemiol 2004; 18: 302-12.
13. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-80.
14. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7.
15. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331-6.
16. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004; 47: 555-8.
17. Data Protection Act, Chapter 29. London: The Stationery Office, 1998.
18. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-70.
19. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8.
20. Evans JM, McMahon AD, Steinke DT, McAlpine RR, MacDonald TM. Do H2-receptor antagonists cause acute pancreatitis? Pharmacoepidemiol Drug Saf 1998; 7: 383-8.
21. The Scottish Office, Home and Health Department. Local Research Ethical Committees. Edinburgh: HMSO, 1992; p. 9.
22. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol 1995; 48: 1441-52.
23. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, nonspecific nonsteroidal anti-inflammatory drugs. Gut 2003; 52: 1-6.
24. Morant SV, Pettitt D, MacDonald TM, Burke TA, Goldstein JL. Application of a propensity score to adjust for channelling bias with NSAIDs. Pharmacoepidemiol Drug Saf 2004; 13: 345-53.
25. Scottish Health Statistics. Appendixes. Available at: http:// www.show.scot.nhs.uk/isdonline/Scottish_Health_Statistics/ SHS98/Appendix.pdf.
26. Pears J, Alexander V, Alexander GF, Waugh NR. Audit of the quality of hospital discharge data. Health Bull 1992; 50: 356-61.
27. Kohli HS, Knill-Jones RP. How accurate are SMR1 (Scottish Morbidity Record 1) data? Health Bull 1992; 50: 14-23.
28. Park RH, McCabe P, Russell RI. Who should log SHIPS? The accuracy of Scottish Hospital Morbidity Data for Wilson's disease. Health Bull 1992; 50: 24-8.
29. Evans JM, Hayes JL, Lipworth BJ, MacDonald TM. Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423-5.
30. MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996; 313: 860-1.
31. Steinke DT, Bain DJ, MacDonald TM, Davey PG. Practice factors that influence antibiotic prescribing in general practice in Tayside. J Antimicrob Chemother 2000; 46: 509-12.
32. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-33.
33. Morris AD, Boyle DIR, McMahon AD, Pearce H, Evans JMM, Newton RW, et al. ACE inhibitor use is associated with hospitalisation for severe hypoglycaemia in patients with diabetes. Diabetes Care 1997; 20: 1363-7.
34. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19: 279-84.
35. Struthers AD, Anderson G, MacFadyen RJ, Fraser C, MacDonald TM. Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activity. Congest Heart Fail 2001; 7: 43-46, 50.
36. McMahon AD, Lipworth BJ, Davey PG, Morris AD, MacDonald TM. Compliance with inhaled corticosteroids and control of asthma. Pharmacoepidemiol Drug Saf 2000; 9: 293-303.
37. McMahon AD, Evans JM, White G, Murray FE, McGilchrist MM, McDevitt DG et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol 1997; 50: 351-6.
38. MacDonald TM, Wei Li. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
39. Morant SV, McMahon AD, Cleland JG, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004; 57: 188-98.
40. Morant SV, Shield MJ, Davey PG, MacDonald TM. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac. Pharmacoepidemiol Drug Saf 2002; 11: 393-400.
41. McMahon AD, Evans JMM, MacDonald TM. Hypersensitivity reactions associated with exposure to naproxen and ibuprofen: a cohort study. J Clin Epidemiol 2001: 54: 1271-4.
42. Donnan PT, Steinke DT, Stubbings C, Davey PG, MacDonald TM. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000; 55: 1785-9.
43. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. The effects of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-34.
44. Struthers AD, Anderson G, Donnan PT, MacDonald TM. Social deprivation increases cardiac hospitalisations in chronic heart failure independently of disease severity and of diuretic non-adherence. Heart 2000; 83: 12-16.
45. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting treatment? Pharmacoepidemiol Drug Saf 2004; 13: 761-6.
46. Evans JM, McMahon AD, McGilchrist MM, White G, Murray FE, McDevitt DG et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995; 311: 22-6.
47. Evans JM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995; 88: 551-7.
48. Evans JM, Macgregor AM, Murray FE, Vaidya K, Morris AD, MacDonald TM. No association between non-steroidal antiinflammatory drugs and acute appendicitis in a case-control study. Br J Surg 1997; 84: 372-4.
49. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997; 40: 619-22.
50. Donnan PT, Wei L, Steinke DT, Phillips G, Clarke R, Noone A et al. Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data. BMJ 2004; 328: 1297-301.
51. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001; 47: 781-7.
52. Evans JMM, Newton RW, Ruta DA, MacDonald TM, Stevenson R, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ 1999; 319: 83-6.
53. Olesen C, de Vries CS, Thrane N, MacDonald TM, Larsen H, Sorensen HT. The EuroMAP Group. Effect of diuretics on fetal growth: a drug effect or confounding by indication? Pooled Danish and Scottish cohort data. Br J Clin Pharmacol 2001; 51: 153-7.
54. Davey PG, McMahon AD, Barbone F, Gillespie WG, Rizvi KA, MacDonald TM. The effect of hip replacement on prescribing of NSAIDs, ulcer healing drugs and hospitalization-a matched cohort study. Pharmacoepidemiol Drug Saf 1999; 8: 423-31.
55. Davey PG, Clarkson P, MaMahon A, MacDonald TM. Costs associated with symptomatic systolic heart failure. Pharmacoeconomics 1999; 16: 399-407.
56. Davey PG, McMahon AD, Irwin D, Anderson P, Morris AD, MacDonald TM. The influence of case mix, site selection and methods biases on costs of hospitalization for acute exacerbations of chronic obstructive airway disease and lower respiratory tract infections. Value Health 1999; 2: 333-41.
57. Donnan PT, Boyle DI, Broomhall J, Hunter K, MacDonald TM, Newton RW et al. Prognosis following first acute myocardial infarction in type 2 diabetes: a comparative population study. Diabet Med 2002; 19: 448-55.
58. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-42.
59. Steinke DT, Weston TL, Morris AD, MacDonald TM, Dillon JF. The epidemiology of liver disease in Tayside database: a population-based record-linkage study. J Biomed Inform 2002; 35: 186-93.
60. Steinke DT, Weston TL, Morris AD, MacDonald TM, Dillon JF. Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut 2002; 50: 100-5.
61. Flynn RWV, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology and research study (TEARS): thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004; 89: 3879-84.
62. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Paracetamol-related deaths in Scotland, 1994-2000. Br J Clin Pharmacol 2002; 54: 430-2.
63. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Paracetamol toxicity: epidemiology, prevention and costs to the health care system. Q J Med 2003; 95: 609-19.
64. Sheen CL, Dillon JF, Bateman DN, Simpson K, MacDonald TM. Paracetamol pack size restriction: the impact on paracetamol poisoning and over-the-counter supply of paracetamol, aspirin and ibuprofen. Pharmacoepidemiol Drug Saf 2002; 11: 329-31.
65. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, Macdonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998; 7: 275-80.
66. Wang J, Donnan PT, Steinke D, MacDonald TM. The multiple propensity score for analysis of dose-response relationships in drug safety studies. Pharmacoepidemiol Drug Saf 2001; 10: 105-11.
67. Wang J, Donnan PT. Propensity score methods in drug safety studies: practice, strengths and limitations. Pharmacoepidemiol Drug Saf 2001; 10: 341-4.
68. Wang J, Wei L, MacDonald TM. Adjustment using the propensity of adherence: theory, simulation and practical application. Pharmacoepidemiol Drug Saf 2002; 11 (suppl): S207.
69. McMahon AD, MacDonald TM. Design issues for drug epidemiology. Br J Clin Pharmacol 2000; 50: 419-25.
70. McMahon AD, MacDonald TM. Sample size for cohort studies in pharmacoepidemiology. Design issues for drug epidemiology. Pharmacoepidemiol Drug Saf 1997; 6: 331-5.
71. Wang J, Donnan PT. Adjusting for missing data in record linkage outcome studies. J Appl Stat 2002; 29: 873-84.
72. Wang J, Donnan PT, MacDonald TM. An approximate Bayesian risk-analysis for the gastro-intestinal safety of ibuprofen. Pharmacoepidemiol Drug Saf 2002; 11: 695-701.
73. Donnan PT, Wang J. The case-crossover and case-time-control designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2001; 10: 259-62.
74. Morris AD, Boyle DI, McMahon AD, Pearce H, Evans JM, Newton RW, Jung RT, MacDonald TM. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997; 20: 1363-7.
75. Ellis JD, Evans JM, Ruta DA, Baines PS, Leese G, MacDonald TM, Morris AD. Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit. Br J Ophthalmol 2000; 84: 1218-24.
76. Doney AS, Fischer B, Cecil JE, Cohen PT, Boyle DI, Leese G et al. Male preponderance in early diagnosed type 2 diabetes is associated with the ARE insertion/deletion polymorphism in the PPP1R3A locus. BMC Genet 2003; 4: 11.
77. MacDonald TM. The economic evaluation of antibiotic therapy: relevance to urinary tract infection. J Antimicrob Chemother 1994; 33 (suppl A): 137-45.
78. MacDonald TM, Collins D, McGilchrist MM, Stevens J, McKendrick AD, McDevitt DG, Davey PG. The utilisation and economic evaluation of antibiotics prescribed in primary care. J Antimicrob Chemother 1995; 35: 191-204.